Aurobindo pharma Limited has announced a board meeting scheduled for April 6, 2026, to consider a significant corporate action involving the buyback of its fully paid-up equity shares. The pharmaceutical company issued the formal intimation on March 31, 2026, in compliance with regulatory requirements.

Board Meeting Details

The meeting has been convened under Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The board will deliberate on the buyback proposal along with matters necessary and incidental thereto.

Regulatory Compliance and Trading Window

The company has implemented necessary compliance measures in accordance with applicable laws. The trading window for dealing in securities was previously closed for all designated persons, connected persons, and their immediate relatives with effect from April 01, 2026, as per the company's letter dated March 23, 2026.

The trading window restrictions will remain in place until forty-eight hours after the declaration of audited financial results for the financial year ending March 31, 2026. Additionally, the trading window will be deemed closed specifically for the buyback proposal under consideration, ensuring compliance with applicable securities regulations.

Corporate Structure

Aurobindo Pharma Limited operates with its corporate office located at Galaxy, Floors 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad. The company's registered office is situated at Plot No. 2, Maithrivihar, Ameerpet, Hyderabad. The formal communication was signed by B Adi Reddy, Company Secretary & Compliance Officer, ensuring proper corporate governance protocols.

Aurobindo Pharma has announced an extension to its timeline for completing the acquisition of up to 26% stake in Swarnaakshu Solar Power Private Limited. The pharmaceutical company informed stock exchanges that the acquisition will now be completed on or before June 30, 2026, subject to receipt of approval from the concerned state government.

Updated Timeline and Regulatory Status

The company has extended its acquisition timeline due to pending receipt of state government approval for setting up a captive solar power plant. This represents a shift from the previously communicated timeline, as the company continues to await necessary regulatory clearances.

Previous Communications

The company has maintained regular communication with stock exchanges regarding this acquisition, with previous letters dated February 6, 2025, March 28, 2025, June 30, 2025, September 26, 2025, and December 30, 2025. The latest update reflects the ongoing regulatory process required for the captive solar power project.

Strategic Solar Investment

The acquisition remains part of the company's renewable energy strategy, involving both a captive solar power purchase agreement and the equity stake in Swarnaakshu Solar. The investment aligns with the pharmaceutical major's commitment to sustainable energy solutions and operational efficiency through renewable energy adoption.